MTOR and hepatocellular carcinoma: Due to HCC is a highly heterogeneous disease with a variety of deregulated motecular signaling pathways, therefore, identifying reliable biomarkers of those special genetic settings is critical to facilitate the selection of HCC patients who might benefit from mTOR inhibition.